SBI Securities’s Akebia Therapeutics AKBA Stock Holding History

SBI Securities’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$316	Buy	344 +305	+782%	+$328	﹤0.01%	3267
2026 Q2	$44	Sell	39 -4,500	-99%	-$5.36K	﹤0.01%	3698
2026 Q1	$6.31K	Hold	4,539	–	–	﹤0.01%	1933
2025 Q4	$7.31K	Sell	4,539 -14	-0.3%	-$29	﹤0.01%	1867
2025 Q3	$12.4K	Sell	4,553 -2,986	-40%	-$9.9K	﹤0.01%	1662
2025 Q2	$27.4K	Sell	7,539 -94	-1%	-$258	﹤0.01%	1288
2025 Q1	$14.7K	Buy	7,633 +4,500	+144%	+$9.18K	﹤0.01%	1448
2024 Q4	$5.95K	Buy	+3,133	New	+$5.44K	﹤0.01%	1859

Other funds holding AKBA

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return

PFG Private Wealth Management Lutz, Florida $236M AUM 9.86% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Unified Investment Management Atlanta, Georgia $114M AUM 22.27% 1-Year Est. Return

IWN

Independent Wealth Network Urbandale, Iowa $397M AUM 20.36% 1-Year Est. Return

Legacy Private Trust Neenah, Wisconsin $1.83B AUM 13% 1-Year Est. Return

Northern Lights Advisors Seattle, Washington $192M AUM 14.28% 1-Year Est. Return

James J. Burns & Company Melville, New York $937M AUM 13.35% 1-Year Est. Return

SBI Securities's AKBA Position: Q3 2026 in Review

SBI Securities increased its Akebia Therapeutics (AKBA) stake by 782% in Q3 2026, buying an estimated $328 and bringing the position to 344 shares worth $316. The position accounts for ﹤0.01% of the portfolio, ranked #3267.

SBI Securities first reported a position in AKBA in Q4 2024 and has held it in 8 quarters since. The position peaked at $27.4K in Q2 2025. 23 funds tracked by Wall St. Rank hold AKBA as of Q3 2026.

SBI Securities held 344 shares of Akebia Therapeutics worth $316 as of Q3 2026.
SBI Securities bought 305 Akebia Therapeutics shares in Q3 2026, an estimated $328.
Akebia Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #3267 holding.
SBI Securities first reported a position in Akebia Therapeutics in Q4 2024 and has held it in 8 quarters since.
SBI Securities's Akebia Therapeutics position peaked at $27.4K in Q2 2025.
23 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.